London, United Kingdom
Evariste, founded in 2017, is a pioneering company in the United Kingdom that applies artificial intelligence to revolutionize the drug discovery process. Operating within multiple high-impact industries including AI, Biotechnology, Health Care, and Health and Wellness, the company has positioned itself as an innovator in the rapid development of therapeutic compounds.
Central to Evariste's approach is their cutting-edge AI platform, Frobenius, which enables efficient and scalable preclinical drug discovery. The company's focus on developing small molecule inhibitors targeting next-generation synthetic lethality promises transformative potential in addressing unmet medical needs.
Despite Evariste's advancements, there are no disclosed recent investments, providing an opportune window for investors seeking entry into a company that is leveraging AI to push the boundaries of modern drug development. Their slogan, "Applying AI to drug discovery," encapsulates the innovative thrust driving their scientific endeavors.
